Nick Burgin

Nick Burgin is a representative from Eisai, the pharmaceutical company behind lecanemab, who expressed concerns about the NHS's readiness to tackle Alzheimer's disease and criticized the review process that led to the rejection of their drug, stating it would have been denied even if offered for free.